Cardiovascular disease after cancer therapy

European Journal of Cancer, Supplement

Volumn 12, Issue 1, 2014, Pages 18-28

  Aleman, Berthe M P ^a   Moser, Elizabeth C ^b   Nuver, Janine ^c   Suter, Thomas M ^d   Maraldo, Maja V ^e   Specht, Lena ^e   Vrieling, Conny ^f   Darby, Sarah C ^g  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b CHAMPALIMAUD FOUNDATION   (Portugal)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f Clinique des Grangettes   (Switzerland)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cancer; Cardiovascular; Disease; Oncology; Therapy

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CANCER RADIOTHERAPY; CANCER THERAPY; CARDIAC IMAGING; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DOSE RESPONSE; ELECTRIC CONDUCTIVITY; EVIDENCE BASED MEDICINE; FOLLOW UP; GENETIC PREDISPOSITION; HEART; HEART INJURY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MORBIDITY; OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; SMOKING; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC THERAPY;

EID: 84904721840     PISSN: 13596349     EISSN: 18781217     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2014.03.002     Document Type: Article

References (96)

1. Borchmann P., Eichenauer D.A., Engert A. State of the art in the treatment of Hodgkin lymphoma. Nat Rev Clin Oncol 2012, 9(8):450-459.
2. Clarke M., Collins R., Darby S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366(9503):2087-2106.
3. Darby S., McGale P., Correa C., et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011, 378(9804):1707-1716.
4. Hodgson D.C. Late effects in the era of modern therapy for Hodgkin lymphoma. Hematol Am Soc Hematol Educ Prog 2011, 2011:323-329.
5. de Haas E.C., Oosting S.F., Lefrandt J.D., Wolffenbuttel B.H., Sleijfer D.T., Gietema J.A. The metabolic syndrome in cancer survivors. Lancet Oncol 2010, 11(2):193-203.
6. Schultz-Hector S., Trott K.R. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data?. Int J Radiat Oncol Biol Phys 2007, 67(1):10-18.
7. Darby S.C., Cutter D.J., Boerma M., et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys 2010, 76(3):656-665.
8. Gagliardi G., Constine L.S., Moiseenko V., et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl):S77-S85.
9. Aleman B.M., van den Belt-Dusebout A.W., De Bruin M.L., et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007, 109(5):1878-1886.
10. Castellino S.M., Geiger A.M., Mertens A.C., et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011, 117(6):1806-1816.
11. Swerdlow A.J., Higgins C.D., Smith P., et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007, 99(3):206-214.
12. Carr Z.A., Land C.E., Kleinerman R.A., et al. Coronary heart disease after radiotherapy for peptic ulcer disease. Int J Radiat Oncol Biol Phys 2005, 61(3):842-850.
13. Mulrooney D.A., Yeazel M.W., Kawashima T., et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009, 339:b4606.
14. Darby S.C., Ewertz M., McGale P., et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013, 368(11):987-998.
15. Shimizu Y., Kodama K., Nishi N., et al. Radiation exposure and circulatory disease risk: Hiroshima and Nagasaki atomic bomb survivor data, 1950-2003. BMJ 2010, 340:b5349.
16. Preston D.L., Shimizu Y., Pierce D.A., Suyama A., Mabuchi K. Studies of mortality of atomic bomb survivors. Report 13: solid cancer and noncancer disease mortality: 1950-1997. Radiat Res 2003, 160(4):381-407.
17. Hancock S.L., Tucker M.A., Hoppe R.T. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993, 270(16):1949-1955.
18. Heidenreich P.A., Schnittger I., Strauss H.W., et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol 2007, 25(1):43-49.
19. Roychoudhuri R., Robinson D., Putcha V., Cuzick J., Darby S., Moller H. Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study. BMC Cancer 2007, 7:9.
20. Cuzick J., Stewart H., Rutqvist L., et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994, 12(3):447-453.
21. Harris E.E., Correa C., Hwang W.T., et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 2006, (August).
22. Hooning M.J., Botma A., Aleman B.M., et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007, 99(5):365-375.
23. Tukenova M., Guibout C., Oberlin O., et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 2010, 28(8):1308-1315.
24. Maraldo M.V., Brodin N.P., Vogelius I.R., et al. Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2012.
25. Moja L., Tagliabue L., Balduzzi S., et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012, 4:CD006243.
26. Myrehaug S., Pintilie M., Tsang R., et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008, 49(8):1486-1493.
27. Hilbers F.S., Boekel N.B., van den Broek A.J., et al. Genetic variants in TGFbeta-1 and PAI-1 as possible risk factors for cardiovascular disease after radiotherapy for breast cancer. Radiother Oncol 2012, 102(1):115-121.
28. Suter T.M., Ewer M.S. Cancer drugs and the heart: importance and management. Eur Heart J 2013, 34(15):1102-1111.
29. Smith L.A., Cornelius V.R., Plummer C.J., et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010, 10:337.
30. Eschenhagen T., Force T., Ewer M.S., et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011, 13(1):1-10.
31. Ewer M.S., Ali M.K., Mackay B., et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol 1984, 2(2):112-117.
32. de Azambuja A.E., Bedard P.L., Suter T., Piccart-Gebhart M. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?. Target Oncol 2009, 4(2):77-88.
33. de Azambuja E, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac events at 8 years median follow-up in the HERA trial (BIG 1-01). JCO 2014 [in press].
34. Montani D., Bergot E., Gunther S., et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012, 125(17):2128-2137.
35. Harbeck N., Ewer M.S., De Laurentiis M., Suter T.M., Ewer S.M. Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Ann Oncol 2011, 22(6):1250-1258.
36. Cardinale D., Sandri M.T., Martinoni A., et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002, 13(5):710-715.
37. Ky B., Putt M., Sawaya H., et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with Doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 2014, 63(8):809-816.
38. Tassan-Mangina S., Codorean D., Metivier M., et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006, 7(2):141-146.
39. Cardinale D., Colombo A., Lamantia G., et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010, 55(3):213-220.
40. Zhang S., Liu X., Bawa-Khalfe T., et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012, 18(11):1639-1642.
41. Alberti K.G., Eckel R.H., Grundy S.M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645.
42. Mertens A.C., Liu Q., Neglia J.P., et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2008, 100(19):1368-1379.
43. Keating N.L., O'Malley A.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006, 24(27):4448-4456.
44. Nottage K.A., Ness K.K., Li C., Srivastava D., Robison L.L., Hudson M.M. Metabolic syndrome and cardiovascular risk among long-term survivors of acute lymphoblastic leukaemia - from the St. Jude Lifetime Cohort. Br J Haematol 2014.
45. van den Belt-Dusebout A.W., Nuver J., de W.R., et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006, 24(3):467-475.
46. de Haas E.C., Altena R., Boezen H.M., et al. Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol 2013, 24(3):749-755.
47. Nuver J., Smit A.J., Wolffenbuttel B.H., et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005, 23(16):3718-3725.
48. van W.M., Neggers S.J., van der Lelij A.J., Pieters R., van den Heuvel-Eibrink M.M. The metabolic syndrome in adult survivors of childhood cancer, a review. J Pediatr Hematol Oncol 2010, 32(3):171-179.
49. Collier A., Ghosh S., McGlynn B., Hollins G. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review. Am J Clin Oncol 2012, 35(5):504-509.
50. Redig A.J., Munshi H.G. Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy. Am J Med 2010, 123(1). pp. 87.e1-5.
51. Ligibel J. Lifestyle factors in cancer survivorship. J Clin Oncol 2012, 30(30):3697-3704.
52. Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). JCO 2014 [in press].
53. Maraldo M.V., Brodin N.P., Aznar M.C., et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol 2013, 24(8):2113-2118.
54. Darby S.C., McGale P., Taylor C.W., Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005, 6(8):557-565.
55. Travis L.B., Fossa S.D., Schonfeld S.J., et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005, 97(18):1354-1365.
56. McGale P., Darby S.C. Commentary: a dose-response relationship for radiation-induced heart disease-current issues and future prospects. Int J Epidemiol 2008, 37(3):518-523.
57. Brodin N.P., Maraldo M.V., Aznar M.C., et al. Interactive decision-support tool for risk-based radiation therapy plan comparison for hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2014, 88(2):433-445.
58. Daugaard G., Lassen U., Bie P., et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 2005, 7(1):87-93.
59. Aggarwal S., Pettersen M.D., Bhambhani K., Gurczynski J., Thomas R., L'Ecuyer T. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatr Blood Cancer 2007, 49(6):812-816.
60. Bryant J., Picot J., Baxter L., Levitt G., Sullivan I., Clegg A. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review. Eur J Cancer 2007, 43(13):1959-1966.
61. Krawczuk-Rybak M., Dakowicz L., Hryniewicz A., Maksymiuk A., Zelazowska-Rutkowska B., Wysocka J. Cardiac function in survivors of acute lymphoblastic leukaemia and Hodgkin's lymphoma. J Paediatr Child Health 2011, 47(7):455-459.
62. D'Errico M.P., Grimaldi L., Petruzzelli M.F., et al. N-terminal Pro-B-Type natriuretic peptide plasma levels as a potential biomarker for cardiac damage after radiotherapy in patients with left-sided breast cancer. Int J Radiat Oncol Biol Phys 2011.
63. Cardinale D., Sandri M.T. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 2010, 53(2):121-129.
64. Lipshultz S.E., Miller T.L., Scully R.E., et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 2012, 30(10):1042-1049.
65. Newby L.K., Rodriguez I., Finkle J., et al. Troponin measurements during drug development-considerations for monitoring and management of potential cardiotoxicity: an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug Administration. Am Heart J 2011, 162(1):64-73.
66. Cardinale D., Colombo A., Torrisi R., et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010, 28(25):3910-3916.
67. Von Hoff D.D., Layard M.W., Basa P., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979, 91(5):710-717.
68. Slamon D., Eiermann W., Robert N., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011, 365(14):1273-1283.
69. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353(16):1659-1672.
70. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353(16):1673-1684.
71. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002, 20(5):1215-1221.
72. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792.
73. Chien K.R. Herceptin and the heart-a molecular modifier of cardiac failure. N Engl J Med 2006, 354(8):789-790.
74. Barry E., Alvarez J.A., Scully R.E., Miller T.L., Lipshultz S.E. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007, 8(8):1039-1058.
75. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012, 33(14):1787-1847.
76. Turner J.R., Panicker G.K., Karnad D.R., Cabell C.H., Lieberman R., Kothari S. Cardiovascular safety monitoring during oncology drug development and therapy. Am J Ther 2014.
77. Witteles R.M., Telli M. Underestimating cardiac toxicity in cancer trials: lessons learned?. J Clin Oncol 2012, 30(16):1916-1918.
78. Tan-Chiu E., Yothers G., Romond E., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005, 23(31):7811-7819.
79. Forsythe L.P., Parry C., Alfano C.M., et al. Use of survivorship care plans in the United States: associations with survivorship care. J Natl Cancer Inst 2013, 105(20):1579-1587.
80. Stricker C.T., Jacobs L.A., Risendal B., et al. Survivorship care planning after the institute of medicine recommendations: how are we faring?. J Cancer Surviv 2011, 5(4):358-370.
81. Hill-Kayser C.E., Vachani C.C., Hampshire M.K., Di L.G., Jacobs L.A., Metz J.M. Impact of internet-based cancer survivorship care plans on health care and lifestyle behaviors. Cancer 2013, 119(21):3854-3860.
82. Hoppe R.T. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 1997, 8(Suppl. 1):115-118.
83. Ng A.K., Bernardo M.P., Weller E., et al. Long-term survival and competing causes of death in patients with early- stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002, 20(8):2101-2108.
84. Aleman B.M., van den Belt-Dusebout A.W., Klokman W.J., van't Veer M.B., Bartelink H., van Leeuwen F.E. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003, 21(18):3431-3439.
85. Ng A.K., Lacasce A., Travis L.B. Long-term complications of lymphoma and its treatment. J Clin Oncol 2011, 29(14):1885-1892.
86. Hull M.C., Morris C.G., Pepine C.J., Mendenhall N.P. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 2003, 290(21):2831-2837.
87. Galper S.L., Yu J.B., Mauch P.M., et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 2011, 117(2):412-418.
88. Rutqvist L.E., Johansson H. Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer 1990, 61(6):866-868.
89. Rutqvist L.E., Liedberg A., Hammar N., Dalberg K. Myocardial infarction among women with early-stage breast cancer treated with conservative surgery and breast irradiation. Int J Radiat Oncol Biol Phys 1998, 40(2):359-363.
90. Hojris I., Overgaard M., Christensen J.J., Overgaard J. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet 1999, 354(9188):1425-1430.
91. Paszat L.F., Mackillop W.J., Groome P.A., Schulze K., Holowaty E. Mortality from myocardial infarction following postlumpectomy radiotherapy for breast cancer: a population-based study in Ontario, Canada. Int J Radiat Oncol Biol Phys 1999, 43(4):755-762.
92. Vallis K.A., Pintilie M., Chong N., et al. Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer. J Clin Oncol 2002, 20(4):1036-1042.
93. Darby S., McGale P., Peto R., Granath F., Hall P., Ekbom A. Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90 000 Swedish women. BMJ 2003, 326(7383):256-257.
94. Giordano S.H., Kuo Y.F., Freeman J.L., Buchholz T.A., Hortobagyi G.N., Goodwin J.S. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005, 97(6):419-424.
95. Patt D.A., Goodwin J.S., Kuo Y.F., et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol 2005, 23(30):7475-7482.
96. Hooning M.J., Aleman B.M., van Rosmalen A.J., Kuenen M.A., Klijn J.G., van Leeuwen F.E. Cause-specific mortality in long-term survivors of breast cancer: a 25-year follow-up study. Int J Radiat Oncol Biol Phys 2006, 64(4):1081-1091.